<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-151023" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Acute Generalized Exanthematous Pustulosis</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Moore</surname>
            <given-names>Marlyn J.</given-names>
          </name>
          <aff>Uniformed Services University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sathe</surname>
            <given-names>Nishad C.</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Ganipisetti</surname>
            <given-names>Venu Madhav</given-names>
          </name>
          <aff>Presbyterian Hospital</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Marlyn Moore declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Nishad Sathe declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Venu Madhav Ganipisetti declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>3</day>
          <month>5</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-151023.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Acute generalized exanthematous pustulosis (AGEP) is an adverse cutaneous reaction characterized by sterile pinpoint nonfollicular pustules atop an erythematous background. Symptoms most often occur in the setting of medication exposure, such as systemic antibiotics, rapidly become generalized, followed by desquamation and resolution within about two weeks of discontinuing the offending trigger. Although mostly self-limited without systemic involvement, severe cases are classified alongside other cutaneous adverse reactions such as Stevens-Johnson syndrome, toxic epidermal necrolysis, and drug reaction with eosinophilia and systemic symptoms. Treatment is primarily supportive, and the prognosis for complete resolution is excellent. Often regarded as a type IV hypersensitivity reaction, an extensive understanding of the pathophysiology of AGEP is lacking. This activity reviews the evaluation and proposed treatment of AGEP and highlights the role of the interprofessional team in identifying patients with this condition to improve patient care.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the epidemiology of acute generalized exanthematous pustulosis (AGEP).</p></list-item><list-item><p>Review the clinical presentation of AGEP.</p></list-item><list-item><p>Identify the diagnostic findings and histopathologic features of AGEP.</p></list-item><list-item><p>Summarize the role of the interprofessional healthcare team in recognition, work-up, and treatment of this condition.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=151023&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=151023">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-151023.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Acute generalized exanthematous pustulosis (AGEP) is a rare cutaneous adverse reaction in which tiny nonfollicular sterile pustules with underlying erythema develop and spread rapidly.<xref ref-type="bibr" rid="article-151023.r1">[1]</xref>&#x000a0;Initially, AGEP was thought to be a variant of pustular psoriasis until it was described and named as a distinct clinical entity in 1980.<xref ref-type="bibr" rid="article-151023.r2">[2]</xref>&#x000a0;</p>
        <p>Most cases of AGEP occur as an adverse drug reaction, but cases have also been reported following infectious insults or contact with physical triggers.&#x000a0;Although AGEP is often self-limited, it may lead to systemic complications; identification and discontinuation of the triggering agent is the mainstay of treatment.<xref ref-type="bibr" rid="article-151023.r3">[3]</xref><xref ref-type="bibr" rid="article-151023.r4">[4]</xref>&#x000a0;</p>
        <p>Generally classified alongside other severe cutaneous adverse reactions (SCARs) as a type IV hypersensitivity reaction, confirmation of the full breadth of the pathophysiology of AGEP remains under investigation.<xref ref-type="bibr" rid="article-151023.r5">[5]</xref></p>
      </sec>
      <sec id="article-151023.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>The vast majority of reported cases of AGEP are due to an adverse drug reaction, with several cases confirmed via patch testing. Systemic antibiotics are the most commonly implicated agents, particularly beta-lactam antibiotics and macrolides. Other drugs reported to trigger AGEP include hydroxychloroquine, antifungal, antiviral, and antiparasitic drugs, as well as antineoplastic and antirheumatic agents, analgesics, anticonvulsants, and intravenous contrast media, among others. In some cases, even corticosteroids have been reported as the offending drugs.<xref ref-type="bibr" rid="article-151023.r3">[3]</xref><xref ref-type="bibr" rid="article-151023.r6">[6]</xref></p>
        <p>AGEP has been associated with various triggers, including infections, spider bites, contact allergens, herbal remedies, and psoralen-UVA treatment. However, the cause of some cases remains unknown or lacks sufficient confirmation to identify a specific trigger.<xref ref-type="bibr" rid="article-151023.r4">[4]</xref><xref ref-type="bibr" rid="article-151023.r6">[6]</xref></p>
        <p>Certain medications are reported as the suspected cause of AGEP.<xref ref-type="bibr" rid="article-151023.r7">[7]</xref><xref ref-type="bibr" rid="article-151023.r8">[8]</xref><xref ref-type="bibr" rid="article-151023.r9">[9]</xref>&#x000a0;These include, but are not limited to, the following:</p>
        <table-wrap id="article-151023.table0" position="float" orientation="portrait">
          <table style="width: 412px;" border="1" cellspacing="1" cellpadding="20">
            <tbody>
              <tr style="height: 13px;">
                <td style="width: 103.265625px; height: 13px;" rowspan="1" colspan="1">
<bold>Antibiotics</bold>
</td>
                <td style="width: 238.734375px; height: 13px;" rowspan="1" colspan="1">Beta-lactams, macrolides, quinolones, tetracyclines, antituberculosis agents, sulfonamides</td>
              </tr>
              <tr style="height: 13px;">
                <td style="width: 103.265625px; height: 13px;" rowspan="1" colspan="1">
<bold>Other anti-infectives</bold>
</td>
                <td style="width: 238.734375px; height: 13px;" rowspan="1" colspan="1">Antifungals, antimalarials, antiprotozoals, antivirals, antihelmintic agents</td>
              </tr>
              <tr style="height: 13px;">
                <td style="width: 103.265625px; height: 13px;" rowspan="1" colspan="1">
<bold>Analgesics</bold>
</td>
                <td style="width: 238.734375px; height: 13px;" rowspan="1" colspan="1">NSAIDs, opioids, acetaminophen,&#x000a0;muscle relaxants</td>
              </tr>
              <tr style="height: 13px;">
                <td style="width: 103.265625px; height: 13px;" rowspan="1" colspan="1">
<bold>Nervous system medications</bold>
</td>
                <td style="width: 238.734375px; height: 13px;" rowspan="1" colspan="1">Anticonvulsants, antidepressants, mood stabilizers, antipsychotics</td>
              </tr>
              <tr style="height: 13px;">
                <td style="width: 103.265625px; height: 13px;" rowspan="1" colspan="1">
<bold>Cardiovascular medications</bold>
</td>
                <td style="width: 238.734375px; height: 13px;" rowspan="1" colspan="1">Calcium channel blockers, beta-blockers, ACE inhibitors, RAAS modulators, diuretics, lipid-lowering agents, antiplatelets</td>
              </tr>
              <tr style="height: 13px;">
                <td style="width: 103.265625px; height: 13px;" rowspan="1" colspan="1">
<bold>Respiratory&#x000a0;medications</bold>
</td>
                <td style="width: 238.734375px; height: 13px;" rowspan="1" colspan="1">Leukotriene receptor antagonists</td>
              </tr>
              <tr style="height: 13px;">
                <td style="width: 103.265625px; height: 13px;" rowspan="1" colspan="1">
<bold>Antineoplastic</bold>
</td>
                <td style="width: 238.734375px; height: 13px;" rowspan="1" colspan="1">Kinase inhibitors, monoclonal antibodies, immunomodulators, chemotherapeutic agents</td>
              </tr>
              <tr style="height: 13px;">
                <td style="width: 103.265625px; height: 13px;" rowspan="1" colspan="1">
<bold>Other</bold>
</td>
                <td style="width: 238.734375px; height: 13px;" rowspan="1" colspan="1">Metformin, proton-pump inhibitors, antihistamines, contrast media, steroids, topical agents, mercury, herbal remedies, vitamins, vaccines, anti-anemic preparations, anesthetics</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
      </sec>
      <sec id="article-151023.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>AGEP is considered a rare condition, with an estimated incidence ranging from one to five cases per million per year.<xref ref-type="bibr" rid="article-151023.r6">[6]</xref>&#x000a0;However, cases of AGEP could&#x000a0;be underreported due to the clinical overlap with other cutaneous drug eruptions and the self-limited nature of most cases that may resolve before referral to a dermatologist.<xref ref-type="bibr" rid="article-151023.r10">[10]</xref><xref ref-type="bibr" rid="article-151023.r11">[11]</xref>&#x000a0;</p>
        <p>The age range of patients with AGEP is broad, as seen in a 2022 case series of 297 patients that included patients from 1 to 93 years old, with patients over 25 most heavily represented, specifically those between 40 and 64 years of age.&#x000a0;Similar to other drug-induced SCARs, AGEP has a female predominance. Women account for approximately 65-80% of reported cases.<xref ref-type="bibr" rid="article-151023.r9">[9]</xref>&#x000a0;</p>
        <p>The onset and resolution of AGEP vary between causative medications with different pharmacokinetics; as such, the female predominance of AGEP may be partly due to differences in drug metabolism compared to men.<xref ref-type="bibr" rid="article-151023.r12">[12]</xref><xref ref-type="bibr" rid="article-151023.r13">[13]</xref>&#x000a0;Given that over 85-90% of cases occur in the setting of drug exposure, the geographic distribution seems to align with countries with higher availability and clinical use of medications, such as pristinamycin in France, known to cause AGEP.<xref ref-type="bibr" rid="article-151023.r14">[14]</xref><xref ref-type="bibr" rid="article-151023.r15">[15]</xref>&#x000a0;</p>
        <p>Other reported correlations with cases of AGEP include patients with HLA-B51, HLA-DR-11, and HLA-DQ3 genotypes associated with T-cell activation, as well as IL-36 receptor antagonist gene mutations resulting&#x000a0;in increased IL-36 signaling.<xref ref-type="bibr" rid="article-151023.r5">[5]</xref></p>
      </sec>
      <sec id="article-151023.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The pathogenesis of AGEP is partially, but not yet fully, understood. AGEP is typically described as a T-cell-mediated type IV hypersensitivity reaction with neutrophilic inflammation. After exposure to a triggering factor, such as a new medication, host proteins bind drug metabolites to form an epitope captured by antigen-presenting cells. Drug-specific CD4+ and CD8+ cells are then activated&#x000a0;and migrate to the skin,&#x000a0;then cytotoxic proteins (perforin, granzyme B, Fas ligand) are released to induce keratinocyte apoptosis. This creates vesicles that become sterile pustules as neutrophils are recruited via CXCL8 and IL-8. Interferon-gamma (IFN gamma) propagates additional neutrophil recruitment via additional CXCL8, while granulocyte-macrophage colony-stimulating factor (GM-CSF) protects the neutrophils from apoptosis.<xref ref-type="bibr" rid="article-151023.r5">[5]</xref></p>
        <p>The innate immune system's involvement has also been implicated based on elevated IL-17 and IL-22 in peripheral blood samples of AGEP patients. Th17 cells produce IL-17 and IL-22, which stimulate additional IL-8 production from keratinocytes, thereby propagating neutrophil recruitment and pustule formation.<xref ref-type="bibr" rid="article-151023.r7">[7]</xref><xref ref-type="bibr" rid="article-151023.r16">[16]</xref>&#x000a0;</p>
        <p>Furthermore, IL-36 gene mutations resulting in dysregulated IL-36 signaling have been associated with AGEP, implying participation of&#x000a0;the IL-36 pro-inflammatory cytokine cascade in the propagation of this condition.<xref ref-type="bibr" rid="article-151023.r10">[10]</xref>&#x000a0;Increased IL-4 and IL-5 cytokine production have also been reported in some cases, which could explain the peripheral eosinophilia and eosinophilic infiltrates in AGEP skin.<xref ref-type="bibr" rid="article-151023.r5">[5]</xref>&#x000a0;Overall, additional studies are needed to elucidate the pathogenesis of AGEP further.</p>
      </sec>
      <sec id="article-151023.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Histopathologic findings consistent with AGEP include non-follicular spongiform pustules within the epidermis, particularly within and below the stratum corneum (causing a subcorneal dermatosis), edema of the papillary dermis with neutrophilic and eosinophilic perivascular infiltrates.<xref ref-type="bibr" rid="article-151023.r5">[5]</xref><xref ref-type="bibr" rid="article-151023.r8">[8]</xref>&#x000a0;Additional features include necrotic keratinocytes, the potential confluence between the intraepidermal and subcorneal pustules, and mixed inflammatory dermal and interstitial infiltrates.<xref ref-type="bibr" rid="article-151023.r6">[6]</xref><xref ref-type="bibr" rid="article-151023.r10">[10]</xref>&#x000a0;</p>
        <p>Specifically, when differentiating between pustular psoriasis and AGEP, AGEP has necrotic keratinocytes, spongiosis of the epidermis, mixed neutrophilic and eosinophilic infiltrates, and lacks the dilated blood vessels within the dermal papillae that are classically described in psoriasis.<xref ref-type="bibr" rid="article-151023.r11">[11]</xref><xref ref-type="bibr" rid="article-151023.r12">[12]</xref></p>
        <p>Although not typically performed in the analysis of skin biopsies, gene expression profiling of AGEP skin shows increased <italic toggle="yes">IL36G </italic>expression compared to healthy skin, and immunohistochemical analysis shows a strong presence of IL-36 alpha and IL-36 gamma in the pustules as well as the peri-pustular epidermis of AGEP biopsies.<xref ref-type="bibr" rid="article-151023.r7">[7]</xref></p>
      </sec>
      <sec id="article-151023.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>The appearance of AGEP is described as tiny nonfollicular sterile pustules with underlying erythema that develop and spread rapidly and are accompanied by pruritus or burning sensation plus an actual or subjective fever. Although often described as &#x0201c;pinhead&#x0201d; size, the pustules may coalesce, appear more prominent, and lead to superficial skin detachment with gentle pressure akin to a positive Nikolsky sign.<xref ref-type="bibr" rid="article-151023.r17">[17]</xref>&#x000a0;</p>
        <p>Symptoms begin in flexural or intertriginous regions before becoming more generalized to the trunk, limbs, and face within a few hours to days while usually sparing palms and soles.<xref ref-type="bibr" rid="article-151023.r6">[6]</xref><xref ref-type="bibr" rid="article-151023.r10">[10]</xref>&#x000a0;Mucosal surfaces are not typically involved, but when they are, this involvement is often restricted to the oral and buccal mucosa.<xref ref-type="bibr" rid="article-151023.r17">[17]</xref>&#x000a0;</p>
        <p>Over the next 1&#x000a0;to 2 weeks, the pustules desquamate in a collaret-like manner.&#x000a0;Other reported symptoms include lymphadenopathy or atypical presentations that include purpura, vesicles, bullae, or symptoms localized to the face, neck, and chest.&#x000a0;Historical clues consistent with AGEP include rapid development of symptoms, often within ten days or less of exposure to an offending medication, and resolution within 15 days of discontinuation.<xref ref-type="bibr" rid="article-151023.r3">[3]</xref><xref ref-type="bibr" rid="article-151023.r8">[8]</xref>&#x000a0;</p>
        <p>In some cases, such as AGEP triggered by hydroxychloroquine or terbinafine, the time&#x000a0;from onset&#x000a0;to resolution may be much longer.<xref ref-type="bibr" rid="article-151023.r12">[12]</xref><xref ref-type="bibr" rid="article-151023.r18">[18]</xref></p>
      </sec>
      <sec id="article-151023.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>In addition to a detailed history, physical exam, and medication reconciliation, a punch biopsy that includes a pustule and blood tests is useful to aid in diagnosis and to evaluate for systemic involvement.<xref ref-type="bibr" rid="article-151023.r11">[11]</xref>&#x000a0;Useful lab tests include a complete blood count (CBC), a comprehensive metabolic panel (CMP) to include renal and liver function tests (LFT), and C-reactive protein (CRP).<xref ref-type="bibr" rid="article-151023.r17">[17]</xref>&#x000a0;</p>
        <p>The presence or absence of other symptoms and hemodynamic stability of a patient will dictate the urgency and setting (outpatient versus inpatient) in which this workup occurs. Suppose a patient's clinical presentation overlaps with other severe cutaneous adverse reactions, such as Stevens-Johnson syndrome or toxic epidermal necrolysis. In that case, they may require an evaluation and care at a specialized burn unit.<xref ref-type="bibr" rid="article-151023.r19">[19]</xref></p>
        <p>A scoring system published in 2001 by Sidoroff et al., often called the EuroSCAR criteria or AGEP validation score, includes clinical information, lab results, and histopathologic findings. These criteria stratify cases into the likelihood that AGEP is the underlying diagnosis.</p>
        <p>According to these metrics, a score of 0 or below rules out the possibility of AGEP. A score of 1&#x000a0;to 4 cannot rule out AGEP, whereas a score of 5&#x000a0;to 7 indicates that AGEP is probable. A score of 8&#x000a0;to 12 is considered to diagnose AGEP definitively. These criteria are shown.<xref ref-type="bibr" rid="article-151023.r6">[6]</xref><xref ref-type="bibr" rid="article-151023.r8">[8]</xref></p>
        <p>
<bold>Exanthem Features</bold>
</p>
        <list list-type="order">
          <list-item>
            <p>No pustules or unable to determine (0), Pustules present and equivocal (+1), Pustules present in significant number, nonfollicular, and minuscule/"pinhead" &#x0003c; 5 mm size, can be&#x000a0;confluent (+2).</p>
          </list-item>
          <list-item>
            <p>No erythema or unable to determine (0), Erythema present and equivocal (+1), Erythema present and widespread as a base upon which the pustules are located (+2).</p>
          </list-item>
          <list-item>
            <p>Unable to determine distribution pattern (0), Distribution pattern equivocal (+1), Distribution begins in intertriginous regions or face with rapid spread to trunk and limbs (+2).</p>
          </list-item>
          <list-item>
            <p>No post-pustular desquamation or unable to determine (0), Post-pustular desquamation (+1).</p>
          </list-item>
        </list>
        <p>
<bold>Other Features</bold>
</p>
        <list list-type="order">
          <list-item>
            <p>Mucosal involvement (- 2), no mucosal involvement (0).</p>
          </list-item>
          <list-item>
            <p>Onset &#x0003e; 10 days (-2), onset &#x0003c;= 10 days (0).</p>
          </list-item>
          <list-item>
            <p>Resolution &#x0003e; 15 days (-4), resolution &#x0003c;= 15 days (0)</p>
          </list-item>
          <list-item>
            <p>Temperature &#x0003c; 38 degrees C (100.4 degrees F) (0), Fever &#x0003e;- 38 degrees C (100.4 degrees F) (+1).</p>
          </list-item>
          <list-item>
            <p>WBC &#x0003c; 7,000 cells/mm^3 (0), WBC &#x0003e;= 7,000 cells/mm^3 (+1)</p>
          </list-item>
        </list>
        <p>
<bold>Histologic Features</bold>
</p>
        <list list-type="order">
          <list-item>
            <p>Consistent with another diagnosis (-10).</p>
          </list-item>
          <list-item>
            <p>Not representative or no histology (0).</p>
          </list-item>
          <list-item>
            <p>Peripheral neutrophil exocytosis (+1).</p>
          </list-item>
          <list-item>
            <p>Non-spongiform subcorneal and/or intraepidermal or nonspecified pustules with papillary edema (+2), Spongiform subcorneal and/or intraepidermal or nonspecific pustules without papillary edema (+2).</p>
          </list-item>
          <list-item>
            <p>Spongiform subcorneal and/or intraepidermal pustules with papillary edema (+3).</p>
          </list-item>
        </list>
        <p>In addition to clinical evaluation and biopsy, attempting to confirm the culprit medication may be appropriate in cases of polypharmacy. Any diagnostic tests that involve symptom provocation should not be attempted until at least six weeks after the complete resolution of symptoms. Patch testing is the preferred approach, with intradermal or prick tests potentially useful if patch testing is negative and the benefits outweigh the risks.<xref ref-type="bibr" rid="article-151023.r6">[6]</xref>&#x000a0;The estimated sensitivity of patch testing for AGEP is up to 58%; therefore, a negative patch test result cannot rule out a potential triggering agent.<xref ref-type="bibr" rid="article-151023.r20">[20]</xref></p>
        <p>Ex vivo tests such as the lymphocyte transformation test (LTT) and enzyme-linked immunospot assay (ELISpot) have potential utility but currently are limited in their clinical use. One potential benefit is that these tests do not rely on re-creating the patient's symptoms and may be more desirable for patient comfort. Drawbacks of these tests include lack of availability at many healthcare facilities, the requirement for well-preserved and viable T-lymphocytes from the patient, and wide variation in sensitivity for delayed hypersensitivity reactions. The reported sensitivity is between 27% and 74% for LLT and 35% to 85% for ELISpot.<xref ref-type="bibr" rid="article-151023.r21">[21]</xref></p>
      </sec>
      <sec id="article-151023.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Treatment involves discontinuing the offending agent and providing supportive care such as topical ceramides and prevention of secondary infection with proper skin hygiene. Additional supportive treatments include topical corticosteroids, antipyretics, and antihistamines.<xref ref-type="bibr" rid="article-151023.r5">[5]</xref><xref ref-type="bibr" rid="article-151023.r21">[21]</xref>&#x000a0;</p>
        <p>Treatments reported for some inpatient cases include systemic corticosteroids, cyclosporine, acitretin, dapsone, infliximab, and intravenous immune globulin (IVIG).<xref ref-type="bibr" rid="article-151023.r4">[4]</xref>&#x000a0;In cases of severe or refractory AGEP, there may be a role for systemic steroids or cyclosporine, with the potential to escalate to infliximab and intravenous immune globulin; however, these treatments are not routinely indicated. Evidence-based guidelines for AGEP that fail to respond to supportive therapy do not yet exist, as current recommendations are based on case studies without controlled studies.<xref ref-type="bibr" rid="article-151023.r5">[5]</xref>&#x000a0;</p>
        <p>For patients with a history of AGEP, empiric avoidance of the suspected trigger and appropriate documentation of an adverse drug reaction history in the patient&#x02019;s medical record is appropriate.<xref ref-type="bibr" rid="article-151023.r6">[6]</xref></p>
      </sec>
      <sec id="article-151023.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Since the course of AGEP has pustular and desquamative phases, the differential diagnosis includes pustular psoriasis, subcorneal pustular dermatosis (Sneddon-Wilkinson disease), varicelliform eruption, pustular vasculitis, staphylococcal scalded skin syndrome, pustular erythema multiforme, bullous impetigo, bullous tinea, pemphigus foliaceous, pemphigus erythematosus, pemphigus vulgaris, and other severe cutaneous adverse reactions and drug eruptions such as Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), or drug reaction with eosinophilia and systemic symptoms (DRESS).<xref ref-type="bibr" rid="article-151023.r5">[5]</xref><xref ref-type="bibr" rid="article-151023.r8">[8]</xref><xref ref-type="bibr" rid="article-151023.r17">[17]</xref>&#x000a0;Pustular psoriasis is typically the most difficult to differentiate from AGEP.</p>
      </sec>
      <sec id="article-151023.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The prognosis for AGEP is excellent, and symptoms most often improve or completely resolve within 15 days of medication discontinuation. Still, the recovery timeline may vary depending on the specific pharmacokinetics of the causative agent. The long half-life of hydroxychloroquine is thought to explain prolonged symptoms of AGEP induced by this drug compared to other cases.<xref ref-type="bibr" rid="article-151023.r12">[12]</xref>&#x000a0;</p>
        <p>Identifying a suitable alternative treatment is crucial for a patient's overall well-being if AGEP is caused by a medication they would otherwise take long-term, such as first-line medications for cardiovascular disease, inflammatory arthritis, or epilepsy.</p>
        <p>The previously cited case-fatality rate of 2 to 5% cannot be definitively attributed solely to AGEP without other comorbidities and is therefore disputed.<xref ref-type="bibr" rid="article-151023.r4">[4]</xref>&#x000a0;Recent literature reviews have reported fatalities among patients with AGEP. However, these fatalities were observed in patients whose health was tenuous before the onset of AGEP. Additionally, some patients' AGEP had resolved before their death. Most fatalities were ultimately attributed to sepsis or multi-organ failure.<xref ref-type="bibr" rid="article-151023.r3">[3]</xref></p>
      </sec>
      <sec id="article-151023.s12" sec-type="Complications">
        <title>Complications</title>
        <p>Reported complications of AGEP include bacterial superinfection of desquamating skin, hepatomegaly, lymphadenopathy, liver injury, kidney injury, hypocalcemia, pleural effusions, respiratory distress, agranulocytosis, and even multiorgan involvement. However, reporting bias and retrospective hospital patient data likely influence the reported frequencies.<xref ref-type="bibr" rid="article-151023.r17">[17]</xref><xref ref-type="bibr" rid="article-151023.r22">[22]</xref>&#x000a0;</p>
        <p>One review of 340 AGEP cases in the United States found roughly 8% of patients had acute kidney insult as defined by serum creatinine 1.5 times their baseline, and 8.5% had elevated liver enzymes at least twice the upper limit of normal.&#x000a0;In severe or atypical cases of AGEP refractory to supportive care and medication discontinuation alone, AGEP may mimic septic shock or clinically overlap with TEN or DRESS, with multiorgan involvement requiring additional treatment interventions. Complications are rare, and most cases resolve after stopping the offending medication.<xref ref-type="bibr" rid="article-151023.r10">[10]</xref></p>
      </sec>
      <sec id="article-151023.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Patients can be reassured that AGEP often resolves by discontinuing the causative agent, time, and symptom-guided therapy. The previously cited case-fatality rate of 2 to 5% cannot be definitively attributed solely to AGEP without other comorbidities.<xref ref-type="bibr" rid="article-151023.r3">[3]</xref><xref ref-type="bibr" rid="article-151023.r4">[4]</xref>&#x000a0;Topical steroids, secondary skin infection prevention, and topical moisturizers to rehydrate skin during desquamation are often sufficient treatment measures.<xref ref-type="bibr" rid="article-151023.r11">[11]</xref>&#x000a0;</p>
        <p>If the cause of AGEP is ambiguous, patch or intradermal testing may be considered at least six weeks after complete resolution. However, empiric avoidance of the suspected trigger and appropriate documentation of an adverse drug reaction history in the patient's medical record, without confirmatory testing, is also reasonable.<xref ref-type="bibr" rid="article-151023.r6">[6]</xref></p>
      </sec>
      <sec id="article-151023.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Although AGEP is predominantly self-limited and resolves with discontinuation and avoidance of the triggering agent, the rapid progression of symptoms with associated physical discomfort and potential for secondary infection without proper skincare can be particularly distressing for patients. Lack of proper diagnosis may delay discontinuation of the causative agent or potentially lead to treatment with systemic corticosteroids despite limited evidence that they expedite recovery or shorten disease duration.<xref ref-type="bibr" rid="article-151023.r6">[6]</xref>&#x000a0;</p>
        <p>On the other hand, patients with mild or localized AGEP due to a medication that is otherwise critical to their health with no suitable alternative may be appropriate for continuing the offending drug. For patients to make an informed decision in this hypothetical scenario, further data is needed to clarify the pathogenesis, appropriately characterize the risks of repeated exposures, and develop evidence-based treatment guidelines.</p>
        <p>Collaboration between an interprofessional team of dermatologists, internists, critical care physicians, immunologists, nurses, and other healthcare specialists in clinical and academic settings is required to enhance patient-centered care. Clinical recognition and publication of cases of AGEP in both the inpatient and outpatient setting, controlled trials of specific treatments in severe or refractory cases, and detailed immunologic studies are needed to understand this condition better, clarify the details of its pathogenesis, and establish evidence-based treatment guidelines. Expanding the knowledge base of AGEP will increase diagnostic fidelity, improve patient counseling and reassurance, and develop effective treatment options.</p>
      </sec>
      <sec id="article-151023.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=151023&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=151023">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/skin-problems-and-treatments/acute-generalized-exanthematous-pustulosis/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=151023">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/151023/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=151023">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-151023.s16">
        <fig id="article-151023.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Acute Generalized Exanthematous Pustulosis. Contributed by Venu Ganipisetti, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="IMG_0488" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-151023.s17">
        <title>References</title>
        <ref id="article-151023.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Szatkowski</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Schwartz</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Acute generalized exanthematous pustulosis (AGEP): A review and update.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2015</year>
            <month>Nov</month>
            <volume>73</volume>
            <issue>5</issue>
            <fpage>843</fpage>
            <page-range>843-8</page-range>
            <pub-id pub-id-type="pmid">26354880</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151023.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Beylot</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bioulac</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Doutre</surname>
                <given-names>MS</given-names>
              </name>
            </person-group>
            <article-title>[Acute generalized exanthematic pustuloses (four cases) (author's transl)].</article-title>
            <source>Ann Dermatol Venereol</source>
            <year>1980</year>
            <season>Jan-Feb</season>
            <volume>107</volume>
            <issue>1-2</issue>
            <fpage>37</fpage>
            <page-range>37-48</page-range>
            <pub-id pub-id-type="pmid">6989310</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151023.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vallejo-Yag&#x000fc;e</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Martinez-De la Torre</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mohamad</surname>
                <given-names>OS</given-names>
              </name>
              <name>
                <surname>Sabu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Burden</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>Drug Triggers and Clinic of Acute Generalized Exanthematous Pustulosis (AGEP): A Literature Case Series of 297 Patients.</article-title>
            <source>J Clin Med</source>
            <year>2022</year>
            <month>Jan</month>
            <day>13</day>
            <volume>11</volume>
            <issue>2</issue>
            <pub-id pub-id-type="pmid">35054090</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151023.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Creadore</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Desai</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Alloo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dewan</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Bakhtiar</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cruz-Diaz</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Femia</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fox</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Katz</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Micheletti</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Nelson</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Ortega-Loayza</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Patrinely</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Plovanich</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rosenbach</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shaigany</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Shields</surname>
                <given-names>BE</given-names>
              </name>
              <name>
                <surname>Saleh</surname>
                <given-names>JZ</given-names>
              </name>
              <name>
                <surname>Sharif-Sidi</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Shinkai</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Su</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Wanat</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Wieser</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Wright</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Noe</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Mostaghimi</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Clinical Characteristics, Disease Course, and Outcomes of Patients With Acute Generalized Exanthematous Pustulosis in the US.</article-title>
            <source>JAMA Dermatol</source>
            <year>2022</year>
            <month>Feb</month>
            <day>01</day>
            <volume>158</volume>
            <issue>2</issue>
            <fpage>176</fpage>
            <page-range>176-183</page-range>
            <pub-id pub-id-type="pmid">34985493</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151023.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hadavand</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Kaffenberger</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Cartron</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Trinidad</surname>
                <given-names>JCL</given-names>
              </name>
            </person-group>
            <article-title>Clinical presentation and management of atypical and recalcitrant acute generalized exanthematous pustulosis.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2022</year>
            <month>Sep</month>
            <volume>87</volume>
            <issue>3</issue>
            <fpage>632</fpage>
            <page-range>632-639</page-range>
            <pub-id pub-id-type="pmid">32926975</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151023.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>de Groot</surname>
                <given-names>AC</given-names>
              </name>
            </person-group>
            <article-title>Results of patch testing in acute generalized exanthematous pustulosis (AGEP): A literature review.</article-title>
            <source>Contact Dermatitis</source>
            <year>2022</year>
            <month>Aug</month>
            <volume>87</volume>
            <issue>2</issue>
            <fpage>119</fpage>
            <page-range>119-141</page-range>
            <pub-id pub-id-type="pmid">35187690</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151023.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Meier-Schiesser</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Feldmeyer</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Jankovic</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Mellett</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Satoh</surname>
                <given-names>TK</given-names>
              </name>
              <name>
                <surname>Yerly</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Navarini</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Abe</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Yawalkar</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>WH</given-names>
              </name>
              <name>
                <surname>French</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Contassot</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Culprit Drugs Induce Specific IL-36 Overexpression in Acute Generalized Exanthematous Pustulosis.</article-title>
            <source>J Invest Dermatol</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>139</volume>
            <issue>4</issue>
            <fpage>848</fpage>
            <page-range>848-858</page-range>
            <pub-id pub-id-type="pmid">30395846</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151023.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sidoroff</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Halevy</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bavinck</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Vaillant</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Roujeau</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>Acute generalized exanthematous pustulosis (AGEP)--a clinical reaction pattern.</article-title>
            <source>J Cutan Pathol</source>
            <year>2001</year>
            <month>Mar</month>
            <volume>28</volume>
            <issue>3</issue>
            <fpage>113</fpage>
            <page-range>113-9</page-range>
            <pub-id pub-id-type="pmid">11168761</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151023.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>De</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Das</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sarda</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pal</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Biswas</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Acute Generalised Exanthematous Pustulosis: An Update.</article-title>
            <source>Indian J Dermatol</source>
            <year>2018</year>
            <season>Jan-Feb</season>
            <volume>63</volume>
            <issue>1</issue>
            <fpage>22</fpage>
            <page-range>22-29</page-range>
            <pub-id pub-id-type="pmid">29527022</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151023.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sussman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Napodano</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Are</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hsu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Motaparthi</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Pustular Psoriasis and Acute Generalized Exanthematous Pustulosis.</article-title>
            <source>Medicina (Kaunas)</source>
            <year>2021</year>
            <month>Sep</month>
            <day>23</day>
            <volume>57</volume>
            <issue>10</issue>
            <pub-id pub-id-type="pmid">34684041</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151023.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Feldmeyer</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Heidemeyer</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Yawalkar</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Acute Generalized Exanthematous Pustulosis: Pathogenesis, Genetic Background, Clinical Variants and Therapy.</article-title>
            <source>Int J Mol Sci</source>
            <year>2016</year>
            <month>Jul</month>
            <day>27</day>
            <volume>17</volume>
            <issue>8</issue>
            <pub-id pub-id-type="pmid">27472323</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151023.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chaabouni</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bahloul</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ennouri</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Atheymen</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sellami</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Marrakchi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Charfi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Boudaya</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Amouri</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bougacha</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Turki</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Hydroxychloroquine-induced acute generalized exanthematous pustulosis: a series of seven patients and review of the literature.</article-title>
            <source>Int J Dermatol</source>
            <year>2021</year>
            <month>Jun</month>
            <volume>60</volume>
            <issue>6</issue>
            <fpage>742</fpage>
            <page-range>742-748</page-range>
            <pub-id pub-id-type="pmid">33598928</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151023.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zucker</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Prendergast</surname>
                <given-names>BJ</given-names>
              </name>
            </person-group>
            <article-title>Sex differences in pharmacokinetics predict adverse drug reactions in women.</article-title>
            <source>Biol Sex Differ</source>
            <year>2020</year>
            <month>Jun</month>
            <day>05</day>
            <volume>11</volume>
            <issue>1</issue>
            <fpage>32</fpage>
            <pub-id pub-id-type="pmid">32503637</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151023.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mockenhaupt</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Epidemiology of cutaneous adverse drug reactions.</article-title>
            <source>Allergol Select</source>
            <year>2017</year>
            <volume>1</volume>
            <issue>1</issue>
            <fpage>96</fpage>
            <page-range>96-108</page-range>
            <pub-id pub-id-type="pmid">30402608</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151023.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sidoroff</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dunant</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Viboud</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Halevy</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bavinck</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Naldi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Mockenhaupt</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fagot</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Roujeau</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>Risk factors for acute generalized exanthematous pustulosis (AGEP)-results of a multinational case-control study (EuroSCAR).</article-title>
            <source>Br J Dermatol</source>
            <year>2007</year>
            <month>Nov</month>
            <volume>157</volume>
            <issue>5</issue>
            <fpage>989</fpage>
            <page-range>989-96</page-range>
            <pub-id pub-id-type="pmid">17854366</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151023.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kabashima</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sugita</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sawada</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Hino</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Nakamura</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tokura</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Increased circulating Th17 frequencies and serum IL-22 levels in patients with acute generalized exanthematous pustulosis.</article-title>
            <source>J Eur Acad Dermatol Venereol</source>
            <year>2011</year>
            <month>Apr</month>
            <volume>25</volume>
            <issue>4</issue>
            <fpage>485</fpage>
            <page-range>485-8</page-range>
            <pub-id pub-id-type="pmid">20569282</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151023.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lei</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kang</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <article-title>Current Perspectives on Severe Drug Eruption.</article-title>
            <source>Clin Rev Allergy Immunol</source>
            <year>2021</year>
            <month>Dec</month>
            <volume>61</volume>
            <issue>3</issue>
            <fpage>282</fpage>
            <page-range>282-298</page-range>
            <pub-id pub-id-type="pmid">34273058</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151023.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>de Oliveira</surname>
                <given-names>GV</given-names>
              </name>
              <name>
                <surname>Maia</surname>
                <given-names>MLP</given-names>
              </name>
              <name>
                <surname>Le&#x000e3;o</surname>
                <given-names>FAA</given-names>
              </name>
              <name>
                <surname>Sad</surname>
                <given-names>EF</given-names>
              </name>
              <name>
                <surname>Miotto</surname>
                <given-names>IZ</given-names>
              </name>
              <name>
                <surname>Silva</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Ramos-E-Silva</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>What to expect when AGEP is induced by terbinafine? Case report and critical review of the literature.</article-title>
            <source>Mycoses</source>
            <year>2022</year>
            <month>Oct</month>
            <volume>65</volume>
            <issue>10</issue>
            <fpage>918</fpage>
            <page-range>918-925</page-range>
            <pub-id pub-id-type="pmid">35876217</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151023.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chowdhury</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Talib</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Patricia</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Nye</surname>
                <given-names>KD</given-names>
              </name>
              <name>
                <surname>Moosa</surname>
                <given-names>SA</given-names>
              </name>
            </person-group>
            <article-title>Rare and Complicated Overlap of Stevens-Johnson Syndrome and Acute Generalized Exanthematous Pustulosis.</article-title>
            <source>Cureus</source>
            <year>2021</year>
            <month>Jun</month>
            <volume>13</volume>
            <issue>6</issue>
            <fpage>e15921</fpage>
            <pub-id pub-id-type="pmid">34336425</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151023.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barbaud</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Castagna</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Soria</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Skin tests in the work-up of cutaneous adverse drug reactions: A review and update.</article-title>
            <source>Contact Dermatitis</source>
            <year>2022</year>
            <month>May</month>
            <volume>86</volume>
            <issue>5</issue>
            <fpage>344</fpage>
            <page-range>344-356</page-range>
            <pub-id pub-id-type="pmid">35122269</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151023.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Copaescu</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Ben-Shoshan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Trubiano</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Tools to improve the diagnosis and management of T-cell mediated adverse drug reactions.</article-title>
            <source>Front Med (Lausanne)</source>
            <year>2022</year>
            <volume>9</volume>
            <fpage>923991</fpage>
            <pub-id pub-id-type="pmid">36313986</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151023.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hotz</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Valeyrie-Allanore</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Haddad</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bouvresse</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ortonne</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Duong</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Ingen-Housz-Oro</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Roujeau</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Wolkenstein</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Chosidow</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Systemic involvement of acute generalized exanthematous pustulosis: a retrospective study on 58 patients.</article-title>
            <source>Br J Dermatol</source>
            <year>2013</year>
            <month>Dec</month>
            <volume>169</volume>
            <issue>6</issue>
            <fpage>1223</fpage>
            <page-range>1223-32</page-range>
            <pub-id pub-id-type="pmid">23855377</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
